The Mayo Clinic Cancer Center (MCCC) Clinical Protocol and Data Management (CPDM) functions are administratively overseen by the MCCC Clinical Research Committee (Chaired by the MCCC Deputy Director for Clinical Research) and functionally coordinated by the MCCC Clinical Research Office (CRO), the Data and Safety Monitoring Committee (DSMC), and the Data and Safety Monitoring Board (DSMB). The CPDM functions include clinical research operations and data quality monitoring, facilitated by the Medical Director and Administrative Director and supported by the CRO staff. The CRO carries out development, activation, study maintenance, study coordination, administration, and reporting for all cancer clinical trials conducted at the MCCC. In addition, the CRO provides operational support for the Protocol Review and Monitoring System (PRMS) and the Data and Safety Monitoring (DSM) System. The CPDM and DSM functions at MCCC are distinct from PRMS functions, with minor overlap of membership. Staff in the CRO work collaboratively with the MCCC clinical investigators to provide expert, efficient support in the conduct of clinical research across the enterprise and with individual Disease Groups to ensure efficient development and activation of clinical trials consistent with the priorities of the MCCC Programs. Over the past grant period, the CRO has overseen the development and activation of 617 studies, including an increasingly complex portfolio of studies (e.g., checkpoint inhibitors, CAR T-cells, basket and umbrella trials with targeted therapies). It has provided staffing support in alignment with the growth of the Disease Groups, facilitated the opening of a wide variety of trials in line with Disease Group growth strategies, and maintained stable clinical trial accrual volumes over the last 3 years. With the creation of the integrated Early Cancer Therapeutics (ECTx) unit and the growth of the Cellular Therapy Disease Group, the CRO continues to evolve to efficiently support novel, complex, and innovative trials. Significant progress has been made to improve the clinical trial activation process to address efficiency, time to activation, and quality. Ongoing developments will include the implementation of a new clinical research management system. MCCC provides oversight for participant safety through the Center's DSM system, with functions carried out by the DSMC and the DSMB. The DSMC focuses broadly on safety rather than on individual studies. It evaluates trends in protocol deviations and toxicities and recommends MCCC-wide procedural changes aimed at ensuring that studies are conducted in accordance with MCCC's Data Safety and Monitoring Plan and with federal, local, and institutional policies. The DSMC also reviews the DSM Plan annually and oversees the DSMB functions. The DSMB focuses their review on individual studies, ensuring patient safety by regularly reviewing adverse events on study and responses to the study intervention for individual trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-47
Application #
10113628
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-04-25
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
47
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555

Showing the most recent 10 out of 1129 publications